Navigation Links
The future of interventional cardiology presented at TCT 2008
Date:10/7/2008

  • What do data from the latest studies and trials reveal about stents, and the future of interventional cardiology?
  • What are the newest devices and strategies in the field?
  • How are the new generation of stents performing?
  • How is the role of angioplasty evolving?

TCT 2008 is the annual scientific symposium of the Cardiovascular Research Foundation and the most widely respected forum on these important topics.

Media are encouraged to attend and cover TCT, by clicking on http://www.tctconference.com/index.php?option=com_content&view=article&id=190

Press conferences will be held on the following late breaking trials and registries:

TUESDAY, OCTOBER 14, 9:30 A.M.

  • COOL RCN: A Prospective Randomized Trial Examining the Safety and Efficacy of Systemic Hypothermia for the Prevention of Radiocontrast Nephropathy
  • ISAR-Left Main: A Randomized Comparison of Sirolimus-Eluting and Paclitaxel-Eluting Stents in Unprotected Left Main Coronary Artery Disease
  • FAME: A Prospective Randomized Trial of Fractional Flow Reserve Guided Stenting in Patients with Multivessel Coronary Artery Disease
  • ODESSA: A Prospective Randomized Study Using Optical Coherence Tomography to Evaluate Strut Coverage of Sirolimus-Eluting, Paclitaxel-Eluting, and Zotarolimus-Eluting Coronary Stents
  • DECREASE: A Prospective Registry Examining the Safety and Efficacy of Triple Antiplatelet Therapy After Drug-Eluting Stent Implantation
  • SOS: A Prospective Randomized Trial of Paclitaxel-Eluting Stents vs. Bare-Metal Stents in Saphenous Vein Graft Lesions
  • ENDEAVOR IV: Two-Year Follow-Up from a Prospective Randomized Trial Comparing a Zotarolimus-Eluting Stent and a Paclitaxel-Eluting Stent in Patients with Coronary Artery Disease

WEDNESDAY, OCTOBER 15, 9:00 A.M.

  • ZEST-AMI: A Prospective Randomized Comparison of Zotarolimus-Eluting Stents, Sirolimus-Eluting Stents, and Paclitaxel-Eluting Stents in Patients with Acute Myocardial Infarction
  • PREPARE: A Prospective Randomized Trial of Proximal Microcirculatory Protection in Patients with Acute Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention
  • ARNO: A Prospective Randomized Trial Comparison of Bivalirudin and Unfractionated Heparin Plus Protamine in Patients Undergoing Elective Percutaneous Coronary Intervention
  • NAPLES: A Prospective Randomized Trial Comparison of Bivalirudin and Unfractionated Heparin Plus Tirofiban in Patients with Diabetes Mellitus Undergoing Elective Percutaneous Coronary Intervention
  • PROBI VIRI: A Prospective Randomized Trial of an Extended Bivalirudin Infusion in Patients Undergoing Percutaneous Coronary Intervention
  • ASSIST: A Prospective Randomized Trial Evaluating Early Eptifibatide Administration in Patients with Acute Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention After Thienopyridine Loading
  • FATA: A Prospective Randomized Trial of Tirofiban and Abciximab in Patients with Acute Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention
  • HORIZONS-AMI: A Prospective Randomized Trial of Paclitaxel-Eluting Stents vs. Bare-Metal Stents in Patients with Acute ST-Segment Elevation Myocardial Infarction
  • HORIZONS-AMI: A Prospective Randomized Trial of Bivalirudin vs. Unfractionated Heparin Plus Glycoprotein IIb/IIIa Inhibitors in Patients with Acute ST-Segment Elevation Myocardial Infarction: Long-Term Follow-Up and Interaction with Stent Type

THURSDAY, OCTOBER 16, 9:00 A.M.

  • SORT-OUT III: A Prospective Randomized Comparison of Zotarolimus-Eluting Stents and Sirolimus-Eluting Stents in Patients with Coronary Artery Disease
  • BBC ONE: A Prospective Randomized Comparison of a Single Drug-Eluting Stent Provisional Strategy vs. Routine Dual Drug-Eluting Stents for Coronary Bifurcation Lesions
  • ISAR-TEST-2: A Prospective Randomized Trial Comparing Polymer-Free Rapamycin-Eluting and Probucol-Eluting Stents, Polymer-Based Sirolimus-Eluting Stents, and Zotarolimus-Eluting Stents in Patients with Coronary Artery Disease
  • ESTROFA-2: A Large-Scale Registry Examining the Rates of Stent Thrombosis After Implantation of Zotarolimus-Eluting and Everolimus-Eluting Stents in Patients with Coronary Artery Disease
  • EMPIRE: A Multicenter Registry Evaluating Neuroprotection During Carotid Stenting with a Novel Flow Reversal System
  • EPIC: A Multicenter Registry Evaluating Neuroprotection During Carotid Stenting with a Novel Distal Protection Device First in Human Report: Initial Experience with a Stentless and Retrievable Percutaneous Aortic Valve Prosthesis
  • DIVERGE: A Large-Scale Registry Evaluating a Novel Self-Expanding Drug-Eluting Bifurcation Stent: Clinical, Angiographic, and IVUS Results Western Denmark Heart Registry: A Large-Scale Registry Examining the Safety and Efficacy of Zotarolimus-Eluting and Sirolimus-Eluting Stents in Patients with Coronary Artery Disease


'/>"/>

Contact: Judy Romero
jromero@crf.org
212-851-9311
Cardiovascular Research Foundation
Source:Eurekalert

Related medicine news :

1. Plastic Surgery 2008 to Showcase Future of Plastic Surgery Through Groundbreaking Research
2. A look to the future
3. Campaign for Americas Future Co-Director Roger Hickey Available to Discuss the Future of Health Care Under the Obama and McCain Administrations
4. More Older Americans Seeking Online Resources to Plan for Their Future
5. Social Security Disability Can Be Key to Financial Future
6. Florida Hospital Unveils New Details, Name for Childrens Hospital of the Future
7. New Research Study Seeks Improved Quality of Life for People in the Future with Schizophrenia
8. Office of the Future Environment Study
9. Office of the future environment study
10. Plexus Consulting Group Works With a USAID-Funded Project to Help the Private Hospitals Association of Jordan Create a Roadmap for the Future
11. Seeding the future: SNM grants grow molecular imaging and nuclear medicine research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... Illinois (PRWEB) , ... March 29, 2017 , ... ... Stencils Device Library for documenting and diagramming network and data center assets and ... , NetZoom subscribers can request new equipment shapes for free and download shapes ...
(Date:3/29/2017)... ... March 29, 2017 , ... Immunotherapy has emerged as one of ... and is touted to be the next revolution in our fight against this complex ... the form of immune checkpoint inhibitors such as PD-1 and PD-L1 inhibitors. , While ...
(Date:3/29/2017)... Richmond, VA (PRWEB) , ... March 29, 2017 , ... ... of its seventh North American office location in Richmond, Virginia, located at the Riverfront ... April 11, attended by Lieutenant Governor of Virginia Ralph S. Northam and Mayor of ...
(Date:3/28/2017)... , ... March 28, 2017 , ... ... is the first technology to directly address the resolution to globally reduce the ... is a patented compound of FDA and TTB approved ingredients that when infused ...
(Date:3/28/2017)... ... 2017 , ... Dr. Isabella Wentz, PharmD, FASCP, one of the leading thyroid ... Thyroid Secret. Dr. Wentz talked about journey and research recently on a blog and ... NOT the only solution to deal with thyroid disease. , Dr. Wentz completed ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... , March 29, 2017  The Pharmaceutical Care ... a new PhRMA report on patient out-of-pocket spending: ... Medicare and Medicaid Services (CMS), the average amount spent ... 13% of drug spending in 2016, down from 23% ... a pricing problem, not a coverage problem. Health plans ...
(Date:3/29/2017)... March 29, 2017  Designers of primary cell wearable ... size by 50% and extend battery life with the ... integrated circuit (PMIC) from Maxim Integrated Products, Inc. (NASDAQ: ... low input voltage of just 0.7V for new high-energy ... Oxide, as well as the more common Alkaline battery ...
(Date:3/29/2017)... 2017   Royal Philips (NYSE: PHG, ... and PathAI, a company that develops artificial intelligence ... to develop solutions that improve the precision and ... diseases. The partnership aims to build deep learning ... artificial intelligence to be applied to massive pathology ...
Breaking Medicine Technology: